Estela Rodriguez and Richard Kim
Aug 2, 2025, 14:31
Estela Rodriguez: Dr Richard Kim on Translating Recent ASCO Colorectal Abstracts into Practice
Estela Rodriguez, Associate Director of Community Outreach- Thoracic Oncology at Sylvester Comprehensive Cancer Center, shared a post on X:
“Great talk by Dr Richard Kim on translating recent ASCO Colorectal abstracts into Practice regarding IO therapy, ctDNA monitoring and treatment escalation.
Translating Evidence to Daily Practice
- Reflex-test up front: Ensure every new stage II-III colon tumor gets MMR/MSI testing at diagnosis so eligible patients aren’t missed.
- Make the combo the default: For every resected stage III dMMR colon cancer patient who can tolerate oxaliplatin, I will recommend mFOLFOX6 (6 mo) plus atezolizumab continued to 12 mo, given the ≥10-point jump in 3-year DFS (86.4 % vs 76.6 %; HR 0.50)
- Flag the knowledge gaps: We still don’t know if chemotherapy is truly needed or how short we can make the IO course-raise this in every consent talk.
- Stage II MSI-high: Continue case-by-case decisions (observation vs brief chemo) or clinical-trial referral; ATOMIC doesn’t yet justify atezolizumab in this setting.”
More posts featuring Estela Rodriguez.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 2, 2025, 14:29
Aug 2, 2025, 14:09
Aug 2, 2025, 13:43
Aug 2, 2025, 13:24
Aug 2, 2025, 13:12
Aug 2, 2025, 13:04